Loading...

ARQT ARCUTIS BIOTHERAPEUTICS INC Investments/Divestments 8-K Filing

RCTS

RQT

ARCUTIS BIOTHERAPEUTICS INC

(ARQT)

2024 8-K

Show Summary

Show Summary

Financial Statements

Management Change

Financial Results

Revenue Announcement

Financial Results

Financial Results

Annual Meeting of Stockholders

Earnings Reports

Appointment of CFO

Public Offering

License Agreement with Sato...

Earnings Reports

Stock Option Exchange Program

Option Exchange Program

Financial Results Press Rel...

Public Offering

Financial Results

Resignation of CFO

License Agreement with Hang...

Earnings Reports

Annual Meeting of Stockholders

Resignation of Senior VP

Earnings Reports

Earnings Reports

External Links:

Arcutis Biotherapeutics, Inc. entered into a License Agreement with Sato Pharmaceutical Co., Ltd. for the development and commercialization of ZORYVE cream and foam in Japan, with upfront and milestone payments.

AI Assistant

ARCUTIS BIOTHERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.